# Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer

> **NCT02055963** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Head And Neck Cancer

## Interventions

- **DRUG:** Minocycline
- **DRUG:** Placebo
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT02055963
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-06
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-11
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Early termination due to the protocol lack of progress in improving accrual rate
- **Last updated:** 2022-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055963, "Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02055963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*